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REVASCULARISATION IN PATIENTS WITH 
CARDIAC ARREST OR ACUTE CORONARY 
SYNDROMES
Coronary Angiography after Cardiac Arrest (COACT) is a 
landmark study that changed the management of patients 
admitted with a cardiac arrest who had successful resuscitation 
and no ST elevation myocardial infarction (STEMI).(1)  In this 
prospective multicentre trial, 552 patients admitted with an 
out of hospital cardiac arrest with an initial shockable rhythm 
who did not have an obvious non-cardiac cause of arrest were 
randomised to immediate coronary angiography and if needed 
coronary revascularisation or delayed coronary angiography 
after neurological recovery. An acute thrombotic occlusion was 
noted only in 3.4% of patients in the immediate angiography 
and in 7.6% of patients in the delayed angiography group. 
Survival rate at discharge (65.2% vs. 68.7%) and at 90-day 
follow-up (64.5% vs. 67.2%) was not different between ran-
domisation groups. In addition, there was no difference for the 
incidence of the composite endpoint survival, with good 
cerebral performance or mild or moderate disability (62.9% vs. 
64.4%). These findings contradict previous observational studies 
that penalised a delayed invasive assessment of the coronary 
artery anatomy and justify both approaches in this setting.
Conversely, the Complete vs. Culprit-Only Revascularisation 
Strategies to Treat Multivessel Disease after Early PCI for 
STEMI (COMPLETE) study confirmed the value of an aggres-
sive revascularisation strategy in patients admitted with a 
STEMI.(2) In this study, 4 041 patients who had multivessel CAD 
were randomised in a 1:1 ratio to complete revascularisation 
vs. culprit-lesion-only PCI. At 3-year follow-up, the incidence of 
the composite endpoint cardiovascular death or myocardial 
infarction (MI) was lower in patients undergoing complete 
revascularisation as compared to the patients that had PCI 
only in the culprit vessel (7.8% vs. 10.5%; p=0.004). Of note, 
the benefit of complete revascularisation was similar in patients 
who had an in-hospital second procedure compared to a 
procedure following readmission within 45 days post-discharge; 
however, this comparison was not randomised, as the choice 
for timing of the second procedure was left to operator’s dis-
cretion. The prognostic value of complete revascularisation in 
patients with non-STEMI has not been fully investigated yet.
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INTRODUCTION
Percutaneous coronary intervention (PCI) research focuses 
on the optimisation of treatment strategies, the development 
of novel equipment and pharmacotherapies for improved 
results, and on risk stratification and identification of high-risk 
patients that will benefit from emerging therapies targeting 
atherosclerotic evolution. Over the last year, important clinical 
studies have been reported that examined the efficacy of 
different treatment strategies and stent platforms in patients 
with obstructive coronary artery disease (CAD), and guidelines 
have been published to provide recommendations about the 
management of these patients. The aim of this article is to 
summarise the findings of the pivotal studies published in 
2019 and to discuss their impact on clinical practice.
* Department of Cardiology, Barts Heart Centre, Barts Health NHS 
Trust, West Smithfi eld, London, United Kingdom 
# Centre for Cardiovascular Medicine and Devices, William Harvey 
Research Institute, Queen Mary University of London, London, 
United Kingdom
† Institute of Cardiovascular Sciences, University College London, 
London, United Kingdom
‡ International Centre for Circulatory Health, Imperial College 
London, London, United Kingdom
∫ The Lambe Institute for Translational Medicine and Curam, Saolta 
University Healthcare Group, National University of Ireland Galway, 
Galway, Ireland
Address for correspondence: 
Prof Andreas Baumbach
Department of Cardiology
Barts Heart Centre
Barts Health NHS Trust
West Smithfi eld
London EC1A 7BE
United Kingdom
Email: 
a.baumbach@qmul.ac.uk 
Andreas Baumbach*,#, Christos V. Bourantas*,#,†, Patrick W. Serruys‡,∫ and William Wijns∫
159
20
20
Vo
lu
m
e 
17
 N
um
be
r 2
CHRONIC CORONARY SYNDROMES
Revascularisation vs. medical therapy
Despite the robust evidence supporting the prognostic impli-
cations of complete revascularisation in patients admitted with 
a STEMI, studies examining the value of PCI in improving out-
comes in patients with a chronic coronary syndrome show 
mixed results. A retrospective analysis including 16 029 patients 
who had positron emission computed tomography myocardial 
perfusion imaging, demonstrated that an early surgical or per-
cutaneous revascularisation was associated with improved 
prognosis in patients with an ischaemic burden >5% - 10%.(3) 
These findings, however, were not confirmed in a  post hoc 
analysis of the Clinical Outcomes Utilising Revascularisation 
and Aggressive Drug Evaluation (COURAGE) trial that 
included 1 379 patients who had stress perfusion imaging and 
quantitative coronary angiography.(4) At 7.9 years of follow-up, 
the extent of CAD – defined by the number of the diseased 
vessels – and not the severity of ischaemia was a predictor of 
survival. Percutaneous coronary intervention in this cohort did 
not improve outcomes over optimal medical therapy; more 
importantly, there was no interaction between the extent of 
ischaemia or CAD and the treatment strategy (i.e. conservative 
vs. PCI).
In line with these findings, the International Study of Compara-
tive Health Effectiveness with Medical and Invasive Approaches 
(ISCHEMIA study) that included 5 179 patients with moderate 
or severe ischaemia in non-invasive imaging, who were ran-
domised to optimal medical therapy or optimal medical therapy 
plus PCI, demonstrated no differences in outcomes between 
groups at 3.3 years of follow-up for the composite endpoint of 
cardiovascular death, MI, admission for unstable angina, heart 
failure symptoms, or resuscitated cardiac arrest (15.5% vs. 
13.8%,  p=0.34).(5)  In this study, PCI was associated with an 
improvement in the quality of life, a reduction in the angina 
symptoms and a lower incidence of spontaneous MI [hazard 
ratio (HR) 0.67, 95% confidence interval (CI) 0.53 - 0.83; 
p<0.01]. An important limitation of the ISCHEMIA study is 
the high (28%) crossover rate from the conservative to the 
invasive arm, which may have affected the reported results; the 
as-treated analysis has not been reported yet.
The association between the presence of viable myocardium, 
surgical revascularisation, and clinical outcomes was recently 
evaluated by a post hoc analysis of the Surgical Treatment for 
Ischaemic Heart Failure (STICH) study.(6)  This analysis, which 
included 601 patients who had a left ventricular ejection frac-
tion ≤35% and viability assessment, failed to demonstrate an 
impact of the presence or absence of myocardial viability on 
the survival benefit noted in patients undergoing surgical 
revascularisation at 10.4-year follow-up. The REVascularisa-
tion for Ischaemic VEntricular Dysfunction (REVIVED) study 
(NCT01920048) is currently examining the safety and efficacy 
of PCI in improving prognosis in patients with heart failure.
PATIENT AND LESION SUBSET
Left main and three-vessel disease
The optimal revascularisation strategy in patients with advanced 
CAD [i.e. 3-vessel disease or left main stem (LMS) disease] and 
in diabetic patients has been discussed in the 2018 European 
Society of Cardiology (ESC) Guidelines on myocardial revas-
cularisation: surgical revascularisation is currently the recom-
mended treatment strategy in diabetic patients with multivessel 
CAD, while PCI has a IIB indication in patients with a SYNTAX 
score ≤22 and is not recommended in patients with a SYNTAX 
score >22.(7)
These recommendations are in line with the findings of 
the Future Revascularisation Evaluation in Patients with Dia-
betes Mellitus: Optimal Management of Multivessel Disease 
(FREEDOM) Follow-On study, which included 1 900 diabetic 
patients with multivessel disease that were randomised to sur-
gical or percutaneous revascularisation and reported a higher 
mortality rate at 8 years of follow-up in the PCI arm compared 
to the surgical revascularisation group (24.3% vs. 18.3%, 
p=0.010).(8) Conversely, the Synergy between PCI with Taxus 
and Cardiac Surgery (SYNTAX) Extended Survival study that 
included 1 689 patients with LMS or three-vessel disease did 
not demonstrate differences in the all-cause mortality between 
patients allocated to PCI and those treated surgically at 10 
years of follow-up (27% vs. 24%, p=0.092). There was, how-
ever, a treatment effect by subgroup interaction according to 
the presence or absence of 3-vessel disease; mortality was 
increased in the PCI group compared to the coronary artery 
bypass graft (CABG) arm (HR 1.41, 95% CI 1.10 - 1.80), while 
there were no differences between the 2 groups in patients 
with LMS disease (HR 0.90, 95% CI 0.68 - 1.20); conversely, 
there was no difference in outcomes for the 2 treatment 
strategies in diabetic and non-diabetic patients (P-for interac-
tion 0.660).(9) A limitation of both studies is the fact that the 
patients in the PCI arm were treated with a 1st generation 
drug-eluting stent (DES) that is not currently used in con-
temporary practice, and the fact that they both reported only 
all-cause mortality instead of patient-orientated cardiovascular 
endpoints.
The Evaluation of XIENCE vs. Coronary Artery Bypass Surgery 
for Effectiveness of Left Main Revascularisation (EXCEL) study 
overcame these limitations; in this study, 1 905 patients with 
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LMS disease and SYNTAX score ≤32 were randomised to 
PCI with a 2nd generation DES or CABG.(10)  In the PCI arm, 
intravascular ultrasound (IVUS) imaging was used in 77.2% of 
the cases.(11) At 5-year follow-up, there were no differences 
between groups for the combined endpoint of all-cause death, 
MI, or stroke (22.0% in the PCI arm vs. 19.2% in the CABG 
group; p=0.13). The event rate at 30-day follow-up was lower 
in the PCI arm (4.9% vs. 8.0%), there was no difference between 
groups for the period 30 days - 1 year (4.1% vs. 3.8%), while for 
the period 1 - 5 years of follow-up a higher event rate was 
reported in patients undergoing PCI (15.1% vs. 9.7%). Patients 
randomised to CABG were more likely to suffer a cere-
brovascular event (5.2% vs. 3.3%), while those treated with PCI 
had increased all-cause mortality (13.0% vs. 9.9%) and more 
often ischaemia-driven revascularisation (16.9% vs. 10.0%). 
Similarly to what has been reported in the SYNTAX study, 
there was no difference in the outcomes between the 2 treat-
ment strategies in diabetic and non-diabetic patients at 3- and 
5-year follow-up.(10,12)
Percutaneous coronary intervention of 
bifurcation stenoses
In 2019, the 3-year follow-up data of the DKCRUSH V study 
were published; similar to what has been reported at 1-year 
follow-up, the double kiss-crush technique was associated 
with a lower incidence of target lesion revascularisation (TLR, 
5.0% vs. 10.3%,  p=0.029) target vessel MI (1.7% vs. 5.8%, 
p=0.017), and definite or probable stent thrombosis (0.4% vs. 
4.1%,  p=0.006) compared to provisional T-stenting.(13)  The 
double kiss-crush technique, however, is a challenging pro-
cedure and requires skills and expertise; therefore, considering 
that the findings of the DKCRUSH V study may not be 
reproduced by centres with less experienced operators, the 
recently published 14th consensus document from the 
European Bifurcation Club advocates the use of a provisional 
T-stenting technique for the treatment of bifurcation lesions 
and proposes a 2-stent strategy only in lesions with a complex 
anatomy, when access to the side branch is challenging, or 
when there is ostial disease in the side branches extending 
>5mm form the carina and/or increased calcification.(14) In the 
case of a 2-stent strategy, the European Bifurcation Club 
recommends the use of culotte or the TAP technique and 
when the crush technique is considered it proposes the use of 
the double kiss-crush.
Treatment of chronic total occlusions
In 2019, the EuroCTO Club published a consensus document 
that summarises the current evidence (Figure 1), discusses the 
indications for chronic total occlusion (CTO) revascularisation, 
presents the advances in CTO equipment, and provides 
recommendations about training in CTO PCI.(15)  In line with 
the ESC guidelines on myocardial revascularisation and taking 
into account the findings of randomised controlled studies, the 
EuroCTO Club recommends CTO recanalisation in the pre-
sence of symptoms despite optimal medical therapy; in asymp-
tomatic patients, ischaemic burden assessment is recom-
mended and CTO revascularisation is advised if there is 
evidence of increased ischaemic burden (≥10% of the left 
ventricular mass). These recommendation are in line with the 
findings of the recently reported Drug-Eluting Stent Implanta-
tion vs. Optimal Medical Treatment in Patients With Chronic 
Total Occlusion (DECISION-CTO) trial.(16)  In this study, 815 
patients with a CTO were randomised in a 1:1 ratio to complete 
revascularisation or to the treatment of the obstructive non-
CTO lesions whenever these were present. Only one-fourth of 
the patients included in the 2 groups had a single-vessel disease. 
At 4-year follow-up, there was no difference between the 2 
groups for the combined endpoint of death, MI, stroke, or 
revascularisation (22.4% vs. 22.3%, p=0.86) or patients’ quality 
of life. These findings indicate that in case of multivessel disease, 
revascularisation of the non-CTO lesion and re-evaluation of 
the extent of ischaemia and patient symptoms should be con-
sidered before advocating recanalisation of a CTO. Limitations 
of the study – the largest of its kind – included the high 
crossover rate (19.6%) from the non-CTO PCI group to the 
CTO-PCI group within the first days from randomisation, as 
well the fact that it was underpowered for the primary endpoint 
as patient recruitment was terminated early because of a slow 
enrolment rate.
Small vessel and in-stent restenosis
Percutaneous coronary intervention in small vessels has been 
associated with a higher incidence of major adverse cardio-
vascular events (MACE) and TLR due to in-stent restenosis. 
In 2019, a pre-specified sub-analysis of the Biodegradable 
Polymer and Durable Polymer Drug-eluting Stents in an All 
Comers Population (BIO-RESORT) study was published, which 
compared outcomes following PCI in small vessels (<2.5mm) 
using ultrathin-strut cobalt chromium biodegradable polymer 
sirolimus-eluting stents (strut thickness 71μm) or very thin-strut 
platinum chromium biodegradable polymer everolimus-eluting 
stents (strut thickness 78μm) or previous-generation thin strut 
cobalt-chromium durable polymer zotarolimus-eluting stents 
(strut thickness 102μm). A higher incidence of TLR was noted 
in the thicker strut zotarolimus-eluting stent than in the 
ultrathin-strut sirolimus-eluting stent group (5.3% vs. 2.1%, 
p=0.006), while there was no difference in the TLR rate 
between the everolimus and zotarolimus-eluting stent groups 
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FIGURE 1: Summary of the findings of the 3 randomised control trials comparing percutaneous coronary intervention and 
medical therapy in patients with a total chronic occlusion.
Reproduced with permission from ref.(15)  Percutaneous recanalisation of chronic total occlusions: 2019 consensus document from the EuroCTO 
Club. Page no. 198 - 208, Copyright 2019, with permission from Europa Digital & Publishing. This content is not covered by the terms of the 
CC BY-NC 4.0 Open Access agreement. Please refer to the original rightsholder.
Explore Eurocto Impactor-CTO
Location & design Europe & Canada
Multicentre RCT (14 centres)
Europe
Multicentre RCT (28 centres)
Russia
Single-centre RCT
N patients 304 407 72
Study population Patients with STEMI treated with 
PCI with a non-infarct-related CTO
SCAD CTO patients with symptoms 
and/or ischaemia and viability
Patients with isolated dominant 
RCA CTO and stable angina
Primary endpoint
LVEF and LVEDV by CMR QoL (SAQ, EQ-5D)
          Stress                Rest
ΔMIB by a adenosine stress CMR
Follow-up period 4 months 1 year 1 year
Mean J-CTO score 2 ± 1 1.82 ± 1.07 1.92 ± 0.86
Success rate
Positive/negative
Major fi ndings
100
75
50
25
0
Explore
73.0
100
75
50
25
0
Eurocto
86.6 100
75
50
25
0
Impactor-CTO
83.0
      PCI                 OMT
No difference
N/A
N/A
No difference
PCI of a CTO located in the 
LAD may improve LVEF and 
clinical outcome
MACE
QoL
 Ischaemia reduction
 LVEF and LVEDV
      PCI                 OMT
No difference
    Better
N/A
N/A
      PCI                 OMT
No difference
    Better
    Better
N/A
CMR = cardiac magnetic resonance, CTO = chronic total occlusion, EQ-5D= EuroQol 5 dimensions questionnaire, J-CTO = Japanese chronic total occlusion, LAD = left anterior 
descending, LVEDV = left ventricular end-diastolic volume, LVEF = left ventricular ejection fraction, MACE = major adverse cardiovascular events, OMT = optimal medical therapy, 
PCI = percutaneous coronary intervention, QoL = quality of life, RCA = right coronary artery, RCT = randomised control trial, SAQ = Seattle Angina Questionnaire, SCAD = stable 
coronary artery disease, STEMI = ST-segment elevation myocardial infarction, ΔMIB = decrease in myocardial ischaemia burden.
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(4.0% vs. 5.1%, p=0.31).(17) These findings convincingly highlight 
the prognostic implications of strut thickness in small vessels in 
the DES era and are in line with previous studies reporting 
outcomes in bare-metal stents.(18)
In-stent restenosis represents the most common cause of 
stent failure; its treatment is challenging and is associated with 
poor prognosis and a high TLR rate.(19)  The 2 most effective 
treatment strategies today are drug-coated balloon angioplasty 
or DES implantation. In 2019, the Difference in Anti-restenotic 
Effectiveness of Drug-eluting stent and drug-coated balloon 
AngiopLasty for the occUrrence of coronary in-Stent restenosis 
(DAEDALUS) patient-level meta-analysis was published, which 
included 1 976 patients treated with a paclitaxel-coated balloon 
or a DES.(20)  At 3-year follow-up, paclitaxel-coated balloon 
angioplasty was associated with a higher incidence of TLR 
compared to DES implantation (HR 1.32, 95% CI 1.02 - 1.70; 
p=0.035); however, there was no difference between groups 
for the combined endpoint of death, MI, or target lesion 
thrombosis (Figure 2).
EXISTING AND EMERGING 
INTERVENTIONAL DEVICES
Drug-eluting stents and bioresorbable scaffolds
The ESC Guidelines on myocardial revascularisation recom-
mend the use of 2nd generation DES in daily clinical prac-
tice.(7) The extended follow-up of the Comparison of Biolimus 
Eluted From an Erodible Stent Coating With Bare Metal Stents 
in Acute ST-Elevation Myocardial Infarction (COMFORTABLE-
AMI) study and the nested intravascular imaging analysis 
published this year has provided further evidence about the 
superiority of DES over bare-metal stents in patients admitted 
with a STEMI. At 5-year follow-up, Biolimus stent implantation 
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FIGURE 2: Summary of the efficacy of paclitaxel-coated balloon angioplasty vs. drug-eluting stent implantation for the 
treatment of patients with in stent restenosis.
Reproduced with permission from ref.(20)  This content is covered by the terms of the CC BY-NC 4.0 Open Access agreement.
Endpoint
Primary effacay endpointa
Primary safety endpointb
All-cause death
Cardiac death
Non-cardiac death
Myocardial infarction
Target lesion thrombosis
Ischaemai-drive target lesion 
revascularisation
Target vessel revascularisation
Net composite endpointc
Net composite endpoint 2d
HR (95% CI)
1.32 (1.02, 1.70)
0.80 (0.58, 1.09)
0.81 (0.53, 1.22)
0.61 (0.32, 1.15)
1.01 (0.58, 1.76)
0.95 (0.61, 1.48)
1.14 (0.45, 2.90)
1.39 (1.06, 1.84)
1.15 (0.91, 1.46)
1.07 (0.87, 1.32)
0.97 (0.80, 1.19)
Drug-eluting stentPaclitaxel-coated balloon
a = Primary efficacy endpoint: target lesion revascularisation, b = Primary safety endpoint: the composite of death, myocardial infarction, or target lesion thrombosis, c = Net composite 
endpoint: the composite of death, myocardial infarction, target lesion thrombosis, or target lesion revascularisation, d = Net composite endpoint: the composite of death, myocardial 
infarction, target lesion thrombosis, or target vessel revascularisation.
163
20
20
Vo
lu
m
e 
17
 N
um
be
r 2
was associated with a lower incidence of target vessel MI 
(2.2% vs. 5.0,  p=0.02) and ischaemia-driven TLR (4.4% vs. 
10.4%, p<0.001) than treatment with a bare-metal stent.(21)
The BIOSTEMI study also focused on the treatment of 
patients with STEMI and randomised 1 300 subjects to ultrathin 
cobalt chromium sirolimus-eluting stent vs. durable polymer 
everolimus-eluting stent implantation. At 12-month follow-up, 
treatment with ultrathin sirolimus-eluting stents was associated 
with a lower incidence of target lesion failure (TLF) than 
everolimus-eluting stents (4% vs. 6%; rate ratio: 0.59, 95% 
Bayesian credibility interval: 0.37 - 0.94; posterior probability of 
superiority 0.986).(22) Conversely, the TALENT study that com-
pared outcomes in all-comer patients randomised to ultrathin 
cobalt chromium sirolimus-eluting stent and durable polymer 
everolimus-eluting stent failed to show a difference for the 
incidence of the composite endpoint of cardiac death, target-
vessel MI, or clinically indicated TLR between groups (4.9% vs. 
5.3%, Pfor non-inferiority <0.0001).(23)
Bioresorbable scaffolds have been introduced to overcome 
the limitations of DES and improve long-term outcomes. How-
ever, the increased event rate reported in these devices at 
short- and intermediate-term follow-up raised concerns about 
their safety and today they are not recommended for routine 
clinical use. A recent meta-analysis of randomised studies com-
paring the Absorb bioresorbable vascular scaffold (BVS) and 
the everolimus-eluting stent showed a higher incidence of TLF 
in the Absorb BVS at 5-year follow-up (14.9% vs. 11.6%, 
p=0.030) that was attributed to a higher incidence of target 
vessel MI and ischaemia-driven TLR.(24)  Landmark analysis 
demonstrated a higher event rate in the Absorb BVS group 
for the period 0 - 3 years of follow-up; however, for the period 
3 - 5 years of follow-up, the incidence of cardiac death, target 
vessel MI, ischaemia-driven TLR, and device thrombosis was 
similar between groups in patients who had not experienced 
an event in the first 3 years. These findings for the first time 
provide unique insights about the timing of the events in 
bioresobable scaffolds and indicate a low event rate at long 
term after their full resorption.
Adjunctive interventional devices
Intravascular lithotripsy (IVL) has emerged over the last years 
as an effective alternative for the treatment of calcified lesions 
that are associated with an increased risk of complications and 
worse prognosis.(25)  It involves the advancement of a catheter 
with a balloon on its tip that contains multiple emitters that 
generate sonic pressure waves that selectively fracture vascular 
calcium without affecting the integrity of the fibroelastic tissue 
of the plaque.(26)  The Shockwave Coronary Rx Lithoplasty 
Study (DISRUPT CAD) was the first study that systematically 
examined the safety and efficacy of IVL in 60 patients with 
heavily calcified lesions and length ≤32mm; the procedure was 
successful in all the lesions resulting in an acute gain of 1.7mm 
and a post-procedural percent diameter stenosis of 12.2%. The 
overall MACE rate at 6 months of follow-up was 8.3%; 3 peri-
procedural MI and 2 cardiac deaths were reported.(27) Similar 
findings were in the DISRUPT CAD II study that included 120 
patients; in that study, the in-hospital MACE rate was 5.8% 
(7 non-Q wave MI), while at 30-day follow-up, the MACE rate 
was 7.6%. Optical coherence tomography (OCT) imaging was 
performed in 48 patients before and in 47 after stenting and 
demonstrated that IVL caused 3.4 ± 2.6 fractures per lesion, 
resulting in an acute gain of 4.79 ± 2.45mm2 and an excellent 
stent expansion of 102.8 ± 30.6%.(28) Recently, Wilson, et al.(29) 
showed that IVL therapy is associated with ventricular ectopics 
and asynchronous pacing. In this study, no malignant arrhyth-
mias were reported; the ongoing DISRUPT CAD III study 
is expected to provide further evidence about the safety 
and efficacy of IVL in the treatment of calcified lesions 
(NCT03595176).
ADJUNCTIVE PHARMACOTHERAPY
The type and the duration of antiplatelet therapy in patients 
undergoing PCI is an area of intensive research. The Ticagrelor 
with Aspirin or Alone in High-Risk Patients after Coronary 
Intervention (TWILIGHT) study was designed to examine the 
optimal duration of dual antiplatelet therapy (DAPT) following 
PCI in high bleeding risk patients.(30)  The study randomised 
7 119 patients to DAPT therapy for 3 months and then treat-
ment with ticagrelor monotherapy or DAPT for 12 months. 
Short duration DAPT was associated with a lower incidence of 
bleeding [rate of Bleeding Academic Research Consortium 
(BARC) type 2, 3, and 5 bleeding: 4.0% in the short duration 
DAPT group vs. 7.1% in the group receiving DAPT for 12 
months,  p<0.001], while there was no difference between 
groups in the incidence of the composite endpoint death, MI, 
or stroke.
Conversely, a  post hoc  analysis of the Global Leaders study 
including 4 570 patients undergoing complex PCI demon-
strated that the experimental regimen of aspirin for 1 month 
and ticagrelor for 24 months was associated with a lower 
incidence of the primary endpoint death, MI at 2 years of 
follow-up compared to conventional DAPT for 12 months, 
and then aspirin monotherapy (3.51% vs. 5.43%; p=0.002). Of 
note, there was no difference between groups in the risk of 
bleeding (incidence of BARC type 3 or 5 bleeding: 2.45% vs. 
2.54%; p=0.834). These findings were confirmed by a patient-
level analysis of 8 randomised control trials including 14  963 
164
patients, which demonstrated that in low bleeding risk patients 
(PREdicting bleeding Complications in patients undergoing 
stent Implantation and SubsequEnt Dual AntiPlatelet Therapy 
score <25) prolonged DAPT therapy was associated with a 
lower incidence of ischaemic events – especially in patients 
undergoing complex PCI. Conversely, long-term DAPT in high 
bleeding risk patients did not reduce the risk of ischaemic 
events and increased the risk of bleeding.(31)
Patients suffering from atrial fibrillation undergoing PCI are at 
increased risk of bleeding as they receive a combination of 
antiplatelet and anticoagulation therapy. The optimal treat-
ment of these patients has been extensively investigated by 
several large scale randomised control studies over recent 
years. The AUGUSTUS trial published this year was a multi-
centre randomised study with a 2 x 2 factorial design that 
randomised 4 614 patients with atrial fibrillation undergoing 
PCI to treatment with a P2Y12 inhibitor, and apixaban or vita-
min K antagonist, and to aspirin or placebo for 6 months.(32) 
The recruited patients received standard of care antithrom-
botic therapy in the first days post-PCI as randomisation to 
study groups was performed 6 (interquartile range 3 - 10) days 
post-intervention. The incidence of major or clinically relevant 
non-major bleeding was higher in patients receiving a vitamin K 
antagonist than those treated with apixaban (14.7% vs. 
10.5%, p<0.001) and in those treated with aspirin than those 
receiving placebo (16.1% vs. 9.0%,  p<0.001). Patients on 
apixaban had a lower incidence of death or hospitalisation 
than the vitamin K antagonist group (23.5% vs. 27.4%, p=0.002) 
and a similar incidence of ischaemic events. Conversely, aspirin 
did not have an effect on these endpoints.
Similar were the findings of the ENTRUST-AF PCI study, which 
investigated in 1 506 patients with atrial fibrillation undergoing 
PCI the safety and efficacy of the combination of a P2Y12 
inhibitor plus edoxaban against the combination DAPT plus 
vitamin K antagonist.(33)  The recruited patients were ran-
domised to the 2 study groups ≈45 h post-PCI. There was no 
difference between groups in the incidence of major bleeding, 
clinically relevant non-significant bleeding or the incidence of 
the composite endpoint of cardiovascular death, stroke, sys-
temic embolic events, MI, and definite stent thrombosis at 12 
months of follow-up. A meta-analysis of randomised con-
trolled trials investigating the safety and efficacy of dual vs. 
triple antithrombotic therapy in patients with atrial fibrillation 
undergoing PCI, published this year, confirmed the above 
findings demonstrating a lower incidence of bleeding (13.4% vs. 
20.8%; p<0.0001) but a higher risk of stent thrombosis (1% vs. 
0.6%; p=0.040) in patients receiving dual therapy.(34)
INVASIVE DIAGNOSTIC TOOLS
Coronary physiology
Recent studies have shown that the fractional flow reserve 
(FFR) and the resting indices including the instantaneous wave 
free ratio (iwFR) have a value not only in guiding revascular-
isation, but also in assessing the final results post-PCI and 
predicting prognosis.(35,36)  There are, however, occasional 
discordances between hyperaemic FFR and resting indices. 
Several studies this year attempted to examine the physio-
logical characteristics of lesions with discordant FFR and iwFR 
and identify lesion types and subgroup of patients where FFR 
should be preferred to iwFR and vice versa.(37,38) A recent sub-
analysis of the Functional Lesion Assessment of Intermediate 
Stenosis to Guide Revascularisation (DEFINE-FLAIR) study 
comparing outcomes in patients with a lesion in the left ante-
rior descending coronary artery deferred from revascularisa-
tion based on the FFR or iwFR estimations showed a lower 
event rate in the iwFR group at 1-year follow-up that was 
attributed to a lower incidence of unplanned revascularisa-
tions (2.22% vs. 4.99%,  p=0.03).(39)  Conversely, a  post hoc 
analysis of the same study in diabetic patients showed no 
differences in outcomes between the FFR and iwFR groups 
(7.2% vs. 10.0%; p=0.30); however, the incidence of non-fatal 
MI was higher in the iwFR group (4.7% vs. 1.9%;  p=0.05), 
with a signif icant interaction for the presence of diabetes 
(p=0.04).(40)
In parallel with the introduction of the resting indices for 
the assessment of the functional severity of intermediate 
lesions, efforts have been made to design computerised-based 
methodologies that are able to post-process coronary angio-
graphy or invasive imaging data to derive FFR. In 2019, 2 new 
solutions have been presented for computational-derived 
FFR: the first relies on 3-dimensional quantitative coronary 
angiography to derive vessel geometry and estimate the pres-
sure drop across a lesion, while the second on the processing 
of OCT imaging data; the latter enables combined morpho-
logical and physiological assessment of atherosclerotic lesions 
and of the procedural results post-PCI.(41,42)  Preliminary vali-
dation of these solutions showed promising results; however, 
further evaluation of their efficacy in a large number of patients 
is required before their broad application in the clinical arena.
Intravascular imaging
Cumulative evidence has highlighted the value of IVUS in 
guiding PCI. A meta-analysis of randomised controlled trials 
published this year including 4 724 patients underscored the 
prognostic benefit of IVUS guidance, demonstrating a lower 
incidence in MACE (5.4% vs. 9.0%;  P  <0.001), cardiac death 
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(0.6% vs. 1.2%,  p=0.03), TLR (3.1% vs. 5.2%,  p=0.001), and 
definite/probable stent thrombosis (0.5% vs. 1.1%,  p=0.02) 
rates in the IVUS-guided compared to the angiography-guided 
group.(43)  In line with the above findings, the 5-year follow-up 
analysis of the Impact of Intravascular Ultrasound Guidance 
on Outcomes of XIENCE PRIME Stents in Long Lesions 
(IVUS-XPL) study, which included 1 400 patients with long 
lesions ≥28mm randomised to IVUS- and angiography-guided 
PCI, reported a lower incidence of MACE (5.6% vs. 10.7%, 
p=0.001) in the IVUS-guided group attributed to a lower inci-
dence of TLR (4.8% vs. 8.4%,  p=0.007). A landmark analysis 
for the follow-up period 1 - 5 years indicated that IVUS 
guidance was associated with clinical benefit at long-term 
follow-up (HR 0.53, 95% CI 0.29 - 0.95;  p=0.031).(44)  These 
findings highlight the prognostic implications of IVUS in guiding 
revascularisation and support its routine use to optimise 
procedural results and improve the short- and long-term out-
comes post-PCI.
Fractional flow reserve is currently recommended to guide 
revascularisation in patients with a chronic coronary syndrome 
and intermediate lesions. The FORZA study examined the 
value of OCT in deferring PCI; the study included 350 patients 
with intermediate lesions who were randomised to OCT- and 
FFR-guided PCI.(45)  Revascularisation in the OCT group was 
performed based on area stenosis and minimum lumen area 
cut-off values, while in the FFR group PCI was performed if 
the FFR was ≤0.80. OCT and FFR were repeated in the 2 
groups and used to optimise stent deployment. At 13 months 
of follow-up, OCT-guided PCI was associated with a higher 
incidence of revascularisation and increased cost while there 
was no difference in the incidence of MACE – defined as the 
composite endpoint of all-cause death, MI, target vessel 
revascularisation – between the FFR- and OCT-guided groups 
(8.0% vs. 3.4%,  p=0.064). For the primary endpoint of the 
study, i.e. the incidence of MACE and significant angina at 13 
months of follow-up, OCT-guided PCI was marginally superior 
to FFR-guidance (14.8% vs. 8.0%, p=0.048). The FROZA study 
is the first that compared in a randomised fashion intravascular 
imaging vs. physiology guided PCI revealing limitations of 
both approaches in guiding revascularisation (i.e. increased 
procedural cost and number of vessels treated in the OCT-
guided group and a higher incidence of MACE and angina 
symptoms in the FFR-guided group). Combined physiology and 
imaging-guided revascularisation is likely to overcome the 
limitations of both modalities and optimise procedural results 
and the clinical outcomes of patients with obstructive CAD.
In 2019, the European Association of Percutaneous Cardio-
vascular Interventions published an expert consensus docu-
ment about the value of intravascular imaging in guiding 
treatment in ACS and in ambiguous coronary angiography 
findings.(46)  This report highlights the value of intravascular 
imaging and in particular of OCT in identifying the culprit lesion, 
when this cannot be detected by coronary angiography and in 
tailoring therapy in patients admitted with an ACS (Figure 3). 
It also underscores the value of intravascular imaging in asses-
sing ambiguous coronary angiographic findings, in detecting 
embolic events and intramural haematomas, in assessing lesions 
caused by an external compression of the vessel by other 
organs, and it summarises the evidence that supports its role in 
identifying vulnerable plaques and high-risk patients (Figure 4).
Non-invasive imaging
Non-invasive functional imaging has an established role in the 
diagnosis of obstructive CAD in symptomatic patients.(47)  In 
the Myocardial Perfusion CMR vs. Angiography and FFR to 
Guide the Management of Patients with Stable Coronary 
Artery Disease (MR-INFORM) study, non-invasive imaging and, 
in particular, cardiac magnetic resonance (CMR) imaging was 
found to be not only useful for the diagnosis of CAD but also 
for guiding revascularisation.(48) In this study, 918 patients were 
randomised to CMR- or FFR-guided revascularisation. CMR-
guided PCI was associated with a lower incidence of coronary 
angiography and PCI (35.7% vs. 45.0%, p=0.005). At 1-year 
follow-up, there was no difference between groups for the 
primary endpoint of all-cause mortality, MI, or target vessel 
revascularisation (3.6% vs. 3.7%, p=0.91). This report is among 
the few that compared the role of non-invasive imaging vs. 
invasive guidance for PCI. A limitation of this study is the fact 
that the event rate was lower than the 10% event rate assumed 
in the power calculation, and thus it may have been under-
powered in detecting differences in outcomes between the 
two study groups.
Similar findings occurred with the Complete Revascularisa-
tion or Stress Echocardiography in Patients With Multivessel 
Disease and ST-Segment Elevation Acute Myocardial Infarc-
tion (CROSS-AMI) study that compared angiography vs. stress 
echocardiography-guided revascularisation in patients admitted 
with a STEMI that had non-culprit lesions with a diameter 
stenosis >50% on quantitative coronary angiography.(49)  The 
study was prematurely stopped after enrolling 77% of the 
patients because of a slow recruitment (n = 306). The authors 
reported a higher incidence of non-culprit lesion revascularisa-
tion in the angiography group (88% vs. 22%). At 1-year follow-
up, there were no differences between groups for the primary 
endpoint of cardiac death, MI, coronary revascularisation, or 
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re-admission because of heart failure (14% vs. 14%, p=0.85). 
A limitation of the CROSS-AMI study was that it was under-
powered to assess differences between groups. Therefore, 
further research is needed to examine the value of non-invasive 
imaging in guiding revascularisation in patients with an ACS.
VULNERABLE PLAQUE AND 
PATIENT DETECTION
The event rate of patients undergoing revascularisation and 
especially of those admitted with an ACS is high at short-term 
follow-up.(50) The identification of high-risk patients has recently 
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FIGURE 3: Value of intravascular imaging in guiding treatment in patients admitted with an acute coronary syndrome.
Intravascular imaging (intravascular ultrasound or optical coherence tomography) can be considered in patients with obstructive coronary artery 
disease in case of a low-risk profile, atypical presentation or complex lesion morphology. In case of multivessel disease, hazy lesions or tortuosity/
eccentricity intravascular imaging can be used to identify the culprit lesion, while in the absence of obstructive coronary artery disease or in the 
presence of normal coronary angiogram when there are regional wall motion abnormalities and electrocardiographic changes invasive imaging can 
be used to exclude a plaque event. Optical coherence tomography can be used to differentiate plaque rupture, plaque erosion, identify an erupted 
calcific nodule, spontaneous coronary dissection, or thromboembolic event; in the absence of a culprit lesion magnetic resonance imaging can be 
considered to identify other causes such as Tako-tsubo cardiomyopathy or myocardial infarction with non-obstructive coronary arteries. 
Reproduced with permission from ref.(46) This content is not covered by the terms of the CC BY-NC 4.0 Open Access agreement. Please refer 
to the original rightsholder.
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FIGURE 4: Summary of the studies investigating the efficacy of intravascular imaging in detecting high-risk plaques and 
patients. The studies’ endpoints, the imaging predictors and the hazard ratio and the confidence interval of the imaging biomarkers are 
summarised, while the positive and negative predictive values are shown only for large-scale studies with more than one imaging biomarker as 
independent predictor.
Study Modality
Number 
of 
patients
Follow-
up 
period
Clinical endpoint Imaging predictors
Hazard ratio 
(95% CI) PPV NPV
Lesion levels 
analysis
Prospect 697 3.4 years
Cardiac death or 
arrest, MI or 
rehospitalisation due 
to unstable or 
progressive angina.
PB ≥70%
MLA ≤4mm2
TCFA
5.03 
(2.51 - 10.11)
3.21 
(1.61 - 6.42)
3.35
(1.77 - 6.36)
18.2% 98.1%
VIVA 170 1.7 years
Death, MI, 
unplanned 
revascularisation.
PB >70%
TCFA
RI
8.13
(1.63 - 40.56)
7.53
(1.12 - 50.55)
2.69
(1.94 - 3.72)
- -
Prediction 506 1 year
PCI because of 
clinical events or 
disease progression 
on angiography.
PB ≥58%
ESS <1Pa
17.57
(3.67 - 84.20)
3.18
(1.20 - 8.43)
41% 92%
LRP 1 563 2 years
Cardiac death or  
arrest, ACS, 
revascularisation, 
readmission for 
angina and >20% 
DS progression on 
angiography.
maxLCBI4mm 
≥400
3.39
(1.85 - 6.20) - -
CLIMA 1 003 1 year
Cardiac death, 
target vessel 
myocardial 
infarction.
MLA <3.5mm2
FCT <75μm
Lipid arc 
>180°
Macrophages
2.07
(1.10 - 4.00)
4.65
(2.40 - 9.00)
2.40
(1.20 - 4.80)
2.66
 (1.20 - 6.10)
18.9% 97%
Patient level 
analysis
Atheroremo
(IVUS) 581 1 year
All cause death, 
ACS, or unplanned 
coronary 
revascularisation.
PB >70%
TCFA
2.83
(1.57 - 5.13)
1.97
(1.09 - 3.57)
20.5% 93.9%
Atheroremo
(NIRS) 203 1 year
All cause death, 
ACS, stroke and 
unplanned coronary 
revascularisation 
exclusive of events 
related to the culprit 
lesion.
LCBI ≥43 5.16(1.73 - 15.42) - -
LRP 1 563 2 years
Cardiac death or 
arrest, ACS, 
revascularisation, 
readmission for 
angina and >20% 
DS progression on 
angiography.
maxLCBI4mm 
≥400
1.89
(1.26 - 2.83) - -
ACS = acute coronary syndrome, CI = confidence interval, DS = diameter stenosis, ESS = endothelial shear stress, FCT = fibrous cap thickness, LCBI = lipid core burden index, 
MI = myocardial infarction, MLA = minimum lumen area, NPV = negative predictive value, PB = plaque burden, PCI = percutaneous coronary intervention, PPV = positive predictive 
value, RI = remodelling index, TCFA = thin cap fibroatheroma.
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attracted attention as novel pharmacotherapies have been 
introduced that appear able to modify atherosclerotic plaque 
and inhibit disease progression. However, these new therapies 
have significant limitations as they are associated with increased 
cost or side effects. Accurate risk stratification and identifica-
tion of high-risk individuals is expected to allow a personalised 
therapy and aggressive treatment of these patients with novel 
medications that appear to improve outcomes in vulnerable 
populations.(51)
Large-scale prospective intravascular imaging studies of 
coronary atherosclerosis have highlighted the value of IVUS in 
detecting vulnerable plaques that are likely to progress and 
cause events and in stratifying more accurately cardiovascular 
risk. In 2019, the Lipid-Rich Plaque (LRP) and the CLIMA 
studies were reported, which, for the first time, assessed the 
efficacy of near-infrared spectroscopy (NIRS)-IVUS and of 
OCT in detecting vulnerable plaques.(52,53)  The LRP registry 
included 1 563 patients with suspected CAD that had coronary 
angiography and possible ad hoc PCI. NIRS-IVUS imaging was 
performed in the non-culprit vessels in at least 2 major coronary 
arteries with length >50mm. At 2-year follow-up, patients 
with increased lipid burden (4mm lipid core burden index, 
maxLCBI4mm  >400) had a higher incidence of non-culprit 
MACE than those with lipid-free plaques (13% vs. 6%, 
p<0.0001). Patient-level (adjusted HR 1.89, 95% CI 1.26 - 
2.83;  p=0.0021) and lesion-level (adjusted HR 3.39, 95% 
CI 1.85 - 6.20;  p<0.0001) analysis demonstrated that 
maxLCBI4mm >400 was an independent predictor of MACE 
at 2-year follow-up. The LRP study provided evidence for the 
prognostic implications of plaque composition, but it failed to 
investigate the synergetic value of NIRS and IVUS in predicting 
events as IVUS analysis was not complete but restricted to 
the 4mm segment with the maxLCBI.
The CLIMA study was a prospective multicentre registry that 
investigated the prognostic implications of OCT-derived plaque 
characteristic in 1 003 patients who had coronary angiography 
for clinical purposes and OCT imaging of the untreated prox-
imal left anterior descending coronary artery.(53) In this study, a 
minimum lumen area <3.5mm2, a lipid arc >180°, a fibrous cap 
thickness <75μm, and the presence of macrophage accumu-
lations were independent predictors of the combined endpoint 
cardiac death and target segment MI. Patients having lesions 
with all the above plaque features had a higher event rate than 
the other patients (18.9% vs. 3.0%, p<0.001).
Advances in coronary imaging
Summarising the results of these studies and taking into 
consideration the findings of previous reports, it appears that 
plaque characteristics provide useful prognostic information at 
a lesion and patient level, but they have a limited accuracy in 
predicting events. Over the last years, several methodologies 
have been introduced to enhance the efficacy of the existing 
modalities in assessing plaque characteristics and an effort has 
been made to develop hybrid-multimodality intravascular 
imaging catheters that will allow a complete assessment of 
plaque morphology and biology. In 2019, the first in man 
application of the combined IVUS-OCT catheter has been 
presented.(54)  In addition, during this year the first in man 
application of a polarisation-sensitive OCT imaging system was 
presented; this modality is expected to enable better plaque 
characterisation and more detailed evaluation of its compo-
nents.(55) Finally, 2 reports have recently examined the efficacy 
of the attenuation compensation technique, a post-processing 
methodology that appears able to enhance OCT imaging 
depth and enables more accurate evaluation of plaque burden 
in heavily diseased segments.(56,57) These reports highlighted the 
potential of this approach in assessing plaque area in heavily 
diseased native vessels, but also demonstrated signif icant 
limitations of this technique, because of imaging artefacts in 
stented segments.
Cumulative evidence has highlighted the implications of the 
local haemodynamic forces on atherosclerotic disease pro-
gression and destabilisation. In 2019, an analysis of the Integrated 
Biomarkers Imaging Study 4 (IBIS-4) showed that the shear 
stress distribution estimated using computational fluid dynamic 
analysis adds value in predicting atherosclerotic disease pro-
gression and changes in plaque morphology, while a meta-
analysis of the Providing Regional Observations to Study Pre-
dictors of Events in the Coronary Tree (PROSPECT) study 
has shown that estimation of plaque stress by processing 
virtual histology-IVUS images enables more accurate identifi-
cation of lesions that will cause events in future.(58,59) Acknow-
ledging the importance of the local haemodynamic forces on 
atherosclerotic disease progression in native and stented 
segments expert recommendations have been recently pub-
lished in a consensus document that describes the existing 
methodologies and their value for research and possibly clinical 
practice in the future.(60)
CONCLUSIONS
Published research in 2019 examining the efficacy of different 
treatment strategies, of emerging or existing devices and of 
the value of coronary physiology or intravascular imaging in 
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PCI planning, has enriched our understanding and modified 
the treatment of patients with obstructive CAD (Figure 5). 
Patients suffering from a STEMI should be treated aggressively, 
aiming for complete revascularisation. Conversely, an initially 
conservative management in patients with an out of hospital 
cardiac arrest without clinical evidence of ongoing acute 
ischaemia seems to be equally effective as an early invasive 
approach. Robust evidence highlights the short- and long-term 
efficacy of DES, while advances in coronary physiology and the 
development of image-based methodologies for the com-
putation of FFR are expected to broaden its use in guiding 
revascularisation. Cumulative data underscore the prognostic 
benefit of intravascular imaging in guiding PCI and in asses-
sing lesion pathology, while advances in intravascular imaging 
and computational modelling are anticipated to allow better 
prediction of vulnerable lesions and of patients at risk that will 
benefit from emerging therapies targeting plaque evolution. 
These developments are expected to improve procedural 
results and long-term outcomes in patients with CAD through 
personalised pharmaco-invasive strategies.
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FIGURE 5: Summary of the important clinical studies published in the field in 2019 that will have an impact on the 
clinical practice.
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